Actuate Therapeutics disclosed that Nasdaq notified it on July 15, 2026, that the company's Market Value of Listed Securities (MVLS) had fallen below the $50 million minimum required for continued listing on the Nasdaq Global Market. The company has 180 calendar days, until January 11, 2027, to regain compliance by maintaining an MVLS of $50 million or more for at least ten consecutive business days. The stock continues trading normally under the symbol ACTU.
View Full Filing (SEC EDGAR)